9 results match your criteria: "National Engineering Technology Research Center of Combined Vaccines[Affiliation]"
Appl Microbiol Biotechnol
March 2025
Wuhan Institute of Biological Products Co., Ltd, No. 1 Huangjin Industrial Park Road, Wuhan, 430207, China.
The baculovirus insect cell expression system is pivotal for exogenous protein expression. However, serial passages of baculovirus in insect cells often result in defective virus generation and a rapid decline in exogenous protein expression, limiting its wider application. Previous studies have shown that the expression of the late expression factor 5 (lef5) from other baculoviruses can enhance the stability of exogenous genes in Autographa californica multiple nucleopolyhedrovirus (AcMNPV).
View Article and Find Full Text PDFViruses
April 2024
Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China.
The enterovirus A71 (EV71) inactivated vaccine is an effective intervention to control the spread of the virus and prevent EV71-associated hand, foot, and mouth disease (HFMD). It is widely administered to infants and children in China. The empty particles (EPs) and full particles (FPs) generated during production have different antigenic and immunogenic properties.
View Article and Find Full Text PDFFront Med
December 2023
China National Biotec Group Company Limited, Beijing, 100029, China.
Confronted with the Coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized.
View Article and Find Full Text PDFVaccine
September 2023
Wuhan Institute of Biological Products Co. Ltd., No. 1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430200, China; National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430200, China. Electronic address: shenshu
The ongoing evolution and emergence of SARS-CoV-2 variants have raised concerns regarding the efficacy of existing vaccines and therapeutic agents. This study aimed to investigate the immunogenicity of an aluminum hydroxide (Alum) and CpG adjuvanted inactivated vaccine (IAV) candidate against SARS-CoV-2 in mice. A comparison was made between the immune response of mice vaccinated with the Alum+CpG adjuvant IAV and those vaccinated with the Alum adjuvant IAV.
View Article and Find Full Text PDFMadin-Darby canine kidney (MDCK) cells are one of the main cell lines used for influenza vaccine production due to their high virus yield and low mutation resistance. Due to their high tumorigenicity, the safety of vaccines produced from these cells is controversial. TGM2 is a multifunctional protein that plays an important role in the adhesion and migration of cells and is associated with tumor formation.
View Article and Find Full Text PDFHum Vaccin Immunother
November 2022
National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China.
Background: A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgently needed.
Methods: To evaluate the safety and immunogenicity of IIV4-W in people aged 3-60 years, 2400 participants recruited in a double-blind phase III trial and were randomly assigned to the IIV4-W, TIV1 and TIV2 groups. The immunogenicity indicators were measured at 28 days postvaccination and for 180 days for safety follow-up.
To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged ≥60 years. In this phase III, randomized, double-blind, active-controlled trial, we compared safety and immunogenicity of IIV4 with a licensed quadrivalent inactivated vaccine (IIV4-HL) produced by Hualan Biological Engineering during the 2019 influenza season. Participants were randomly assigned to receive IIV4 (n = 959) or IIV4-HL (n = 959).
View Article and Find Full Text PDFSci Rep
December 2020
Wuhan Institute of Biological Products Co. Ltd, Wuhan, 430207, China.
Coxsackievirus A6 (CV-A6) and Coxsackievirus A10 (CV-A10) have been emerging as the prevailing serotypes and overtaking Enterovirus A71 (EV-A71) and Coxsackievirus A16 (CV-A16) in most areas as main pathogens of hand, foot and mouth disease (HFMD) in China since 2013. To investigate whole etiological spectrum following EV-A71 vaccination of approximate 40,000 infants and young children in Xiangyang, enteroviruses were serotyped in 4415 HFMD cases from October 2016 to December 2017 using Real Time and conventional PCR and cell cultures. Of the typeable 3201 specimen, CV-A6 was the predominant serotype followed by CV-A16, CV-A10, CV-A5, CV-A2 and EV-A71 with proportions of 59.
View Article and Find Full Text PDFEmerg Microbes Infect
December 2020
Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.